Mabylon AG Breaks New Ground With Promising Peanut Allergy Treatment Trial
Swiss biotech firm Mabylon AG has launched a groundbreaking Phase I clinical trial for its lead compound, MY006, a tri-specific antibod...
No account yet?
Create an Account